一个资源描述框架 (RDF) 模型的命名实体在生物医学文献中的共同出现及其与PubChemRDF的集成
Qingliang Li1, Sunghwan Kim1, Leonid Zaslavsky1
1National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD, 20894, USA.
Journal of cheminformatics
|May 21, 2025
概括
本研究介绍了一种机器可读的数据模型,用于生物医学命名实体的共同发生,增强知识发现. 该模型集成到PubChemRDF中,使研究人员能够查询复杂的生物医学关系.
科学领域:
- 生物医学信息学 生物医学信息学
- 计算生物学 计算生物学
- 数据科学数据科学数据科学
背景情况:
- 生物医学文献包含有关化学物质,基因和疾病等命名实体的关键信息.
- 提取和表示这些实体之间的共发生关联对于构建知识库和知识图来说至关重要.
- 现有的方法在将这些关联表达成机器可读的格式时面临挑战.
研究的目的:
- 开发一种机器可读的数据模型,用于表达生物医学命名实体之间的共发生关联.
- 将此数据模型集成到PubChemRDF资源中,以便公众可以访问.
- 证明模型对生物医学知识发现的实用性.
主要方法:
- 开发了一个资源描述框架 (RDF) 数据模型,用于共同发生的关联.
- 将数据模型集成到PubChemRDF资源中.
- 填充了一个三重商店,命名的实体和协会来源于数百万PubMed引用的文本挖掘.
- 包括用于参考的元数据建模 (作者,期刊,赠款,资助机构).
主要成果:
- 一个公开可访问的PubChemRDF资源,具有集成的共发生数据模型.
- 一个三层楼被提取的生物医学命名实体及其协会所填充.
- 通过多个用例证明了实用性,使生物医学问题的SPARQL查询成为可能.
结论:
- 开发的RDF数据模型有效地以机器可读的格式表示生物医学命名实体共发生协会.
- 整合到PubChemRDF和大量文献数据的人口,促进了先进的生物医学知识探索.
- 该模型使研究人员能够解决复杂的生物医学问题,并从不同角度利用知识.
相关概念视频
01:17Drug Nomenclature
1.6K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.6K
02:40Ligand Binding Sites
12.6K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
12.6K
01:26Drug Discovery: Overview
7.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.3K
01:30Quantitative Aspects of Drug-Receptor Interaction
913
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
913
02:04Covalently Linked Protein Regulators
1.6K
1.6K
01:13Bioavailability: Overview
2.6K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
2.6K